Researchers suggest Vitamin D therapy can tackle diabetes, cancer
New York, May 13: Enhanced activation of Vitamin D by protecting beta cells may be a potential new approach for treating diabetes as well as other diseases, including cancer, researchers have suggested.
When beta cells -- the cells in the pancreas that produce, store and release the hormone insulin -- become dysfunctional, the body cannot make insulin to control blood sugar (glucose) and levels of glucose can rise to dangerous and even fatal levels.
The researchers found that Vitamin D in cells and mouse models can be beneficial in treating these damaged beta cells.
They also provided new insights about gene regulation that could be applied to developing treatments for other diseases, including cancer.
"We know that diabetes is a disease caused by inflammation. We identified the Vitamin D receptor as an important modulator of both inflammation and beta cell survival," said Ronald Evans, from Salk Institute for Biological Studies in California, US.
Using beta cells created from embryonic stem cells, the team was able to identify a compound -- iBRD9 -- that appeared to enhance the activation of the Vitamin D receptor when it was combined with Vitamin D to improve the survival of beta cells.
In the paper, published in the journal Cell, the team conducted a screening test to look for compounds that improved the survival of beta cells in a dish. They then tested the combination in a mouse model of diabetes and showed that it could bring glucose back to normal levels in the animals.
Combining the new compound with vitamin D allowed certain protective genes to be expressed at much higher levels than they are in diseased cells.
"Activating the vitamin D receptor can trigger the anti-inflammatory function of genes to help cells survive under stressed conditions," explained Michael Downes, from the institute.
The researchers noted that although the new compound did not appear to cause any side effects in the mice, further testing is needed before clinical trials can begin.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Allahabad HC orders probe into 'reinstatement' of teacher in UP's Barabanki
Lucknow (PTI): The Lucknow Bench of the Allahabad High Court on Friday ordered a probe by the special task force (STF) into alleged irregularities in the rejoining of a teacher at City Intermediate College in Barabanki, observing that the reinstatement appeared to be prima facie illegal.
The court also directed the recovery of the salary paid to the teacher during the disputed period.
A bench of Justice Rajeev Singh passed the order on a petition filed by the college management committee. The court expressed doubts over the roles of the District Inspector of Schools (DIOS), Barabanki, the college principal and the teacher concerned and hence, directed a detailed inquiry into the matter.
Taking note of alleged manipulation of records and misleading submissions, the court ordered the immediate transfer of the Barabanki DIOS to ensure a fair probe. It also directed the initiation of disciplinary proceedings against the then joint director of education of the Ayodhya division.
In its order, the court found that the teacher, Abhay Kumar, was initially appointed as an assistant teacher in 2018 but joined an Eklavya Model Residential School in Chhattisgarh as a lecturer in June 2024 without obtaining permission from the management. His subsequent request to retain the lien was rejected.
Despite this, he was allowed to rejoin the Barabanki College in September 2025 on the directions of the joint director of education and the DIOS, and was even paid the salary for October 2025. The court termed the rejoining "wholly illegal" and lacking any legal basis.
The bench also expressed concern over lapses in communication within the education department and directed the Uttar Pradesh chief secretary to ensure that official orders are communicated through email and WhatsApp as well, to prevent disputes.
The matter is next listed for hearing on May 28 when a compliance report is sought.
